In-vitro synergism of m-TOR inhibitors, statins, and classical chemotherapy: Potential implications in acute leukemia

Anti-Cancer Drugs

Volumn 19, Issue 7, 2008, Pages 705-712

  Calabro, Anthony ^a   Tai, Julia ^b   Allen, Steven L ^a   Budman, Daniel R ^a,c  

^a Monter Cancer Center   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c North Shore Long Island Center for Advanced Medicine   (United States)

Author keywords

Acute leukemia; AKT; M TOR; Statin; Synergy

Indexed keywords

CYTARABINE; DAUNORUBICIN; EVEROLIMUS; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IDARUBICIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; INDOLE DERIVATIVE; MAMMALIAN TARGET OF RAPAMYCIN; MONOUNSATURATED FATTY ACID; PROTEIN KINASE; PROTEIN KINASE B;

ACUTE LEUKEMIA; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CYTOTOXICITY; DNA FRAGMENTATION; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRENYLATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ACUTE DISEASE; DRUG EFFECT; LEUKEMIA; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SYNERGISM; FATTY ACIDS, MONOUNSATURATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LEUKEMIA; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIROLIMUS;

EID: 51049085142     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328304ae19     Document Type: Article

References (70)

1. Colvin GA, Elfenbein GJ. The latest treatment advances for acute myelogenous leukemia. Med Health R I 2003; 86:243-246.
2. Estey EH. Treatment of acute myelogenous leukemia. Oncology (Williston Park) 2002; 16:343-352, 355-356; discussion 357, 362, 365-366.
3. Kelly LM, Gilliland DG. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 2002; 3:179-198.
4. Rowe JM. Uncertainties in the standard care of acute myelogenous leukemia. Leukemia 2001; 15:677-679.
5. Stirewalt DL, Meshinchi S, Radich JP. Molecular targets in acute myelogenous leukemia. Blood Rev 2003; 17:15-23.
6. Corvera S, Czech MP. Direct targets of phosphoinositide 3-kinase products in membrane traffic and signal transduction. Trends Cell Biol 1998; 8: 442-446.
7. Kim D, Cheng GZ, Lindsley CW, Yang H, Cheng JQ. Targeting the phosphatidylinositol-3 kinase/Akt pathway for the treatment of cancer. Curr Opin Investig Drugs 2005; 6:1250-1258.
8. Mills GB, Kohn E, Lu Y, Eder A, Fang X, Wang H, et al. Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. Semin Oncol 2003; 30:93-104.
9. Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003; 102:972-980.
10. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307:1098-1101.
11. Dos Santos C, Recher C, Demur C, Payrastre B. The PI3K/Akt/mTOR pathway: a new therapeutic target in the treatment of acute myeloid leukemia. Bull Cancer 2006; 93:445-447.
12. Zhao S, Konopleva M, Cabreira-Hansen M, Xie Z, Hu W, Milella M, et al. Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia 2004; 18:267-275.
13. Chow S, Minden MD, Hedley DW. Constitutive phosphorylation of the S6 ribosomal protein via mTOR and ERK signaling in the peripheral blasts of acute leukemia patients. Exp Hematol 2006; 34:1183-1191.
14. Zeng Z, Sarbassov dos D, Samudio IJ, Yee KW, Munsell MF, Ellen Jackson C, et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 2007; 109:3509-3512.
15. Recher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas VM, et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005; 105:2527-2534.
16. Giles FJ, Albitar M. Mammalian target of rapamycin as a therapeutic target in leukemia. Curr Mol Med 2005; 5:653-661.
17. Altman JK, Platanias LC. Exploiting the mammalian target of rapamycin pathway in hematologic malignancies. Curr Opin Hematol 2008; 15: 88-94.
18. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 2004; 24:200-216.
19. Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol 1996; 14:483-510.
20. Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L, et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 2008; 111:379-382.
21. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005; 8:179-183.
22. Dancey JE. Inhibitors of the mammalian target of rapamycin. Expert Opin Investig Drugs 2005; 14:313-328.
23. Tirado OM, Mateo-Lozano S, Notario V. Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax: Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity. Oncogene 2005; 24:3348-3357.
24. Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006; 12:5165-5173.
25. Sassano A, Katsoulidis E, Antico G, Altman JK, Redig AJ, Minucci S, et al. Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Res 2007; 67:4524-4532.
26. Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood 2003; 101:3628-3634.
27. Ho YK, Smith RG, Brown MS, Goldstein JL. Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. Blood 1978; 52:1099-1114.
28. Banker DE, Mayer SJ, Li HY, Willman CL, Appelbaum FR, Zager RA. Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells. Blood 2004; 104:1816-1824.
29. Suarez Y, Fernandez C, Ledo B, Martin M, Gomez-Coronado D, Lasuncion MA. Sterol stringency of proliferation and cell cycle progression in human cells. Biochim Biophys Acta 2005; 1734:203-213.
30. Fernandez C, Lobo Md Mdel V, Gomez-Coronado D, Lasuncion MA. Cholesterol is essential for mitosis progression and its deficiency induces polyploid cell formation. Exp Cell Res 2004; 300:109-120.
31. Connelly-Smith L, Pattinson J, Grundy M, Shang S, Seedhouse C, Russell N, et al. P-glycoprotein is downregulated in KG1a-primitive leukemia cells by LDL cholesterol deprivation and by HMG-CoA reductase inhibitors. Exp Hematol 2007; 35:1793-1800.
32. Newman A, Clutterbuck RD, Powles RL, Millar JL. Selective inhibition of primary acute myeloid leukaemia cell growth by simvastatin. Leukemia 1994; 8:2023-2029.
33. Clutterbuck RD, Millar BC, Powles RL, Newman A, Catovsky D, Jarman M, et al. Inhibitory effect of simvastatin on the proliferation of human myeloid leukaemia cells in severe combined immunodeficient (SCID) mice. Br J Haematol 1998; 102:522-527.
34. Dimitroulakos J, Thai S, Wasfy GH, Hedley DW, Minden MD, Penn LZ. Lovastatin induces a pronounced differentiation response in acute myeloid leukemias. Leuk Lymphoma 2000; 40:167-178.
35. Lewis KA, Holstein SA, Hohl RJ. Lovastatin alters the isoprenoid biosynthetic pathway in acute myelogenous leukemia cells in vivo. Leuk Res 2005; 29:527-533.
36. Xia Z, Tan MM, Wong WW, Dimitroulakos J, Minden MD, Penn LZ. Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia 2001; 15:1398-1407.
37. Goemans BF, Zwaan CM, Harlow A, Loonen AH, Gibson BE, Hahlen K, et al. In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib:identification of T-cell ALL and FAB M5 AML as the most sensitive subsets. Blood 2005; 106:3532-3537.
38. Kornblau SM, Banker DE, Stirewalt D, Shen D, Lemker E, Verstovsek S, et al. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. Blood 2007; 109:2999-3006.
39. Budman DR, Calabro A. Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin:in vitro isobologram studies with conventional and nonconventional cytotoxic agents. Oncology 2006; 70:147-153.
40. Budman DR, Calabro A, Kreis W. In vitro effects of dexrazoxane (Zinecard) and classical acute leukemia therapy:time to consider expanded clinical trials? Leukemia 2001; 15:1517-1520.
41. Budman DR, Calabro A. In vitro search for synergy and antagonism:evaluation of docetaxel combinations in breast cancer cell lines. Breast Cancer Res Treat 2002; 74:41-46.
42. Budman DR, Calabro A. Studies of synergistic and antagonistic combinations of conventional cytotoxic agents with the multiple eico-sanoid pathway modulator LY 293111. Anti-Cancer Drugs 2004; 15:877-881.
43. Budman D, Tai J, Calabro A. Fluvastatin enhancement of trastuzumab and classical cytotoxic agents in defined breast cancer cell lines in vitro. Breast Cancer Res Treat 2007; 104:97-101.
44. Bailly JD, Muller C, Jaffrezou JP, Demur C, Gassar G, Bordier C, et al. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines. Leukemia 1995; 9:799-807.
45. Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K, Ishikawa F, et al. Frequent mutations in the p53 gene in human myeloid leukemia cell lines. Blood 1992; 79:2378-2383.
46. Rizzo MG, Zepparoni A, Cristofanelli B, Scardigli R, Crescenzi M, Blandino G, et al. Wt-p53 action in human leukaemia cell lines corresponding to different stages of differentiation. Br J Cancer 1998; 77:1429-1438.
47. Xie H, Hu Z, Chyna B, Horrigan SK, Westbrook CA. Human mortalin (HSPA9):a candidate for the myeloid leukemia tumor suppressor gene on 5q31. Leukemia 2000; 14:2128-2134.
48. Koeffler HP, Golde DW. Human myeloid leukemia cell lines:a review. Blood 1980; 56:344-350.
49. Niskanen E, Koeffler HP, Golde DW, Cline MJ. Responsiveness of a human myelogenous leukemia cell line (KG-1) to humoral factors in vivo. Leuk Res 1980; 4:203-208.
50. Li Y, Valeriote F, Chen B. Regulation of granulocyte-macrophage colony-stimulating factor (GM-CSF) receptors in a GM-CSF-dependent human myeloid leukemia cell line (AML-193) by interleukin-6. Exp Hematol 1996; 24:94-100.
51. Ciaiolo C, Ferrero D, Pugliese A, Ortolano B, Borrione P, Pileri A. Modulation of in vitro chemosensitivity in acute myelogenous leukemia cell line by GM-CSF:opposing effects observed with different cytotoxic drugs and time exposure. Leuk Res 1999; 23:931-938.
52. Turner AM, Lin NL, Issarachai S, Lyman SD, Broudy VC. FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells. Blood 1996; 88:3383-3390.
53. Jedema I, Barge RM, Willemze R, Falkenburg JH. High susceptibility of human leukemic cells to Fas-induced apoptosis is restricted to G1 phase of the cell cycle and can be increased by interferon treatment. Leukemia 2003; 17:576-584.
54. Kindler V, Shields J, Ayer D, Mazzei GJ. Growth regulation of the AML-193 leukemic cell line:evidence for autocrine production of granulocyte-macrophage colony-stimulating factor (GM-CSF), and inhibition of GM-CSF-dependent cell proliferation by interleukin-1 (IL-1) and tumor necrosis factor (TNF alpha). Int J Cancer 1991; 47:450-454.
55. Valtieri M, Boccoli G, Testa U, Barletta C, Peschle C. Two-step differentiation of AML-193 leukemic line:terminal maturation is induced by positive interaction of retinoic acid with granulocyte colony-stimulating factor (CSF) and vitamin D3 with monocyte CSF. Blood 1991; 77:1804-1812.
56. Mosmann T. Rapid colorimetric assay for cellular growth and survival:application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63.
57. Milton DT, Riely GJ, Azzoli CG, Gomez JE, Heelan RT, Kris MG, et al. Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer 2007; 110:599-605.
58. Liu X, Yue P, Zhou Z, Khuri FR, Sun SY. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst 2004; 96:1769-1780.
59. Mabasa VH, Ensom MH. The role of therapeutic monitoring of everolimus in solid organ transplantation. Ther Drug Monit 2005; 27:666-676.
60. Chou T, Talalay P. Generalized equations for the analysis of inhibition of Michaelis-Menton and higher order kinetic systems with two or more mutually exclusive and non-exclusive inhibitors. Eur J Biochem 1988; 115:207-216.
61. Greco WR, Bravo G, Parsons JC. The search for synergy:a critical review from a response surface perspective. Pharmacol Rev 1995; 47:331-385.
62. Budman DR, Calabro A, Wang LG, Liu XM, Stiel L, Adams LM, et al. Synergism of cytotoxic effects of vinorelbine and paclitaxel in vitro. Cancer Invest 2000; 18:695-701.
63. Zhao L, Wientjes MG, Au JL. Evaluation of combination chemotherapy:integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 2004; 10:7994-8004.
64. Gitler MS, Monks A, Sausville EA. Preclinical models for defining efficacy of drug combinations:mapping the road to the clinic. Mol Cancer Ther 2003; 2:929-932.
65. Stanisic S, Kalaycio M. Treatment of refractory and relapsed acute myelogenous leukemia. Expert Rev Anticancer Ther 2002; 2:287-295.
66. Panwalkar A, Verstovsek S, Giles FJ. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 2004; 100:657-666.
67. Recher C, Dos Santos C, Demur C, Payrastre B. mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle 2005; 4:1540-1549.
68. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005; 16:525-537.
69. Paajarvi G, Roudier E, Crisby M, Hogberg J, Stenius U. HMG-CoA reductase inhibitors, statins, induce phosphorylation of Mdm2 and attenuate the p53 response to DNA damage. Faseb J 2005; 19:476-478.
70. Rathnasabapathy R, Lancet JE. Management of acute myelogenous leukemia in the elderly. Cancer Control 2003; 10:469-477.